Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: A high-value iterative loop

Molecular Therapy

Volumn 16, Issue 6, 2008, Pages 1006-1008

  Liu, Ta Chiang ^a   Hwang, Tae Ho ^a,b   Bell, John C ^a,c   Kirn, David H ^a,d  

^a Jennerex Biotherapeutics   (United States)

^b Pusan National University   (South Korea)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; VIROTHERAPY AGENT;

CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GENE SEQUENCE; GENE TARGETING; GENETIC ENGINEERING; HUMAN; NEOPLASM; NONHUMAN; NOTE; ONCOLYTIC VIROTHERAPY; PRODUCT DEVELOPMENT; TRANSGENE; TUMOR VOLUME; VIRUS REPLICATION;

EID: 44349106062     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.70     Document Type: Note

References (15)

1. Abou-Alfa, GK, Schwartz, L, Ricci, S, Amadori, D, Santoro, A, Figer, A et al. (2006). Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300.
2. Kelly, E and Russell, SJ (2007). History of oncolytic viruses: Genesis to genetic engineering. Mol Ther 15: 651-659.
3. Kirn, D (2001). Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther 8: 89-98.
4. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117.
5. Liu, TC, Hallden, G, Wang, Y, Brooks, G, Francis, J, Lemoine, N et al. (2004). An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther 9: 786-803.
6. McKee, TD, Grandi, P, Mok, W, Alexandrakis, G, Insin, N, Zimmer, JP et al. (2006). Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 66 2509-2513.
7. Wang, Y, Hallden, G, Hill, R, Anand, A, Liu, TC, Francis, J et al. (2003). E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 21: 1328-1335.
8. Gaggar, A, Shayakhmetov, DM and Lieber, A (2003). CD46 is a cellular receptor for group B adenoviruses. Nat Med 9: 1408-1412.
9. Kambara, H, Saeki, Y and Chiocca, EA (2005). Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res 65: 11255-11258.
10. Power, AT and Bell, JC (2007). Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 15: 660-665.
11. Laurie, SA, Bell, JC, Atkins, HL, Roach, J, Bamat, MK, O'Neil, JD et al. (2006). A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res 12: 2555-2562.
12. Thorne, SH, Hwang, TH, O'Gorman, WE, Bartlett, DL, Sei, S, Kanji, F et al. (2007). Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 117: 3350-3358.
13. Wang, Y, Thorne, S, Hannock, J, Francis, J, Au, T, Reid, T et al. (2005). A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res 11: 351-360.
14. Rots, MG, Elferink, MG, Gommans, WM, Oosterhuis, D, Schalk, JA, Curiel, DT et al. (2006). An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents. J Gene Med 8: 35-41.
15. Wein, LM, Wu, JT and Kirn, DH (2003). Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: Implications for virus design and delivery. Cancer Res 63: 1317-1324.